EUVIMEDEUVIMED entdecken
Crossref

Global burden of vaccine‐associated multiple sclerosis, 1967–2022: A comprehensive analysis of the international pharmacovigilance database

Ho Geol Woo, Hyeon Jin Kim, Jaeyu Park, Jinseok Lee, Hayeon Lee, Min Seo Kim, Ai Koyanagi, Lee Smith, Masoud Rahmati iD, Seung Geun Yeo, Dong Keon Yon iD

Journal of Medical Virology · 2024-04 · 96 (4)

DOI: 10.1002/jmv.29591 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medical Virology, online erschienen am 04.04.2024. Verfasst von Ho Geol Woo und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Kyung Hee University Medical Center, Kyung Hee University College of Medicine, Seoul, South Korea. Hauptthemen laut MEDLINE: Multiple Sclerosis, Viral Vaccines, COVID-19. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 47 Literaturangaben. Gefördert von: National Research Foundation of Korea (NRF), Korea Health Industry Development Institute (KHIDI).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Vaccine‐associated multiple sclerosis (MS) is rare, with insufficient evidence from case reports. Given the scarcity of large‐scale data investigating the association between vaccine administration and adverse events, we investigated the global burden of vaccine‐associated MS and potential related vaccines from 1967 to 2022. Reports on vaccine‐associated MS between 1967 and 2022 were obtained from the World Health Organization International Pharmacovigilance Database (total number of reports = 120 715 116). We evaluated global reports, reporting odds ratio (ROR), and information components (IC) to investigate associations between 19 vaccines and vaccine‐associated MS across 156 countries and territories. We identified 8288 reports of vaccine‐associated MS among 132 980 cases of all‐cause MS. The cumulative number of reports on vaccine‐associated MS gradually increased over time, with a substantial increase after 2020, owing to COVID‐19 mRNA vaccine‐associated MS. Vaccine‐associated MS develops more frequently in males and adolescents. Nine vaccines were significantly associated with higher MS reporting, and the highest disproportional associations were observed for hepatitis B vaccines (ROR 19.82; IC 025 4.18), followed by encephalitis (ROR 7.42; IC 025 2.59), hepatitis A (ROR 4.46; IC 025 1.95), and papillomavirus vaccines (ROR 4.45; IC 025 2.01). Additionally, MS showed a significantly disproportionate signal for COVID‐19 mRNA vaccines (ROR 1.55; IC 025 0.52). Fatal clinical outcomes were reported in only 0.3% (21/8288) of all cases of vaccine‐associated MS. Although various vaccines are potentially associated with increased risk of MS, we should be cautious about the increased risk of MS following vaccination, particularly hepatitis B and COVID‐19 mRNA vaccines, and should consider the risk factors associated with vaccine‐associated MS.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Multiple SclerosisViral VaccinesCOVID-19MaleAdolescentHumansCOVID-19 VaccinesmRNA VaccinesPharmacovigilance

Stichwörter der Autor:innen

World Health Organizationglobalvaccinesvaccine‐associated multiple sclerosis

Substanzen

COVID-19 VaccinesmRNA VaccinesViral Vaccines

Autor:innen und Institutionen

  • Department of Neurology, Kyung Hee University Medical Center, Kyung Hee University College of Medicine, Seoul, South Korea.
  • Center for Digital Health, Medical Science Research Institute, Kyung Hee University Medical Center, Kyung Hee University College of Medicine, Seoul, South Korea.
  • Department of Regulatory Science, Kyung Hee University, Seoul, South Korea.
  • Department of Biomedical Engineering, Kyung Hee University, Yongin, South Korea.
  • Medical and Population Genetics and Cardiovascular Disease Initiative, Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.
  • Research and Development Unit, Parc Sanitari Sant Joan de Deu, Barcelona, Spain.

ORCID-Profile: Masoud Rahmati, Dong Keon Yon

Förderung

  • National Research Foundation of Korea (NRF)
  • Korea Health Industry Development Institute (KHIDI)

Zitieren

APA

Woo, H. G., Kim, H. J., Park, J., Lee, J., Lee, H., Kim, M. S., Koyanagi, A., Smith, L., Rahmati, M., Yeo, S. G., & Yon, D. K. (2024). Global burden of vaccine‐associated multiple sclerosis, 1967–2022: A comprehensive analysis of the international pharmacovigilance database. Journal of Medical Virology, 96(4). https://doi.org/10.1002/jmv.29591

Vancouver

Woo HG, Kim HJ, Park J, Lee J, Lee H, Kim MS, et al. Global burden of vaccine‐associated multiple sclerosis, 1967–2022: A comprehensive analysis of the international pharmacovigilance database. Journal of Medical Virology. 2024;96(4). doi:10.1002/jmv.29591

BibTeX
@article{Woo2024,
  author = {Woo, Ho Geol and Kim, Hyeon Jin and Park, Jaeyu and Lee, Jinseok and Lee, Hayeon and Kim, Min Seo and Koyanagi, Ai and Smith, Lee and Rahmati, Masoud and Yeo, Seung Geun and Yon, Dong Keon},
  title = {Global burden of vaccine‐associated multiple sclerosis, 1967–2022: A comprehensive analysis of the international pharmacovigilance database},
  journal = {Journal of Medical Virology},
  year = {2024},
  volume = {96},
  number = {4},
  doi = {10.1002/jmv.29591}
}
Kostenlos starten →